Affordable Access

deepdyve-link
Publisher Website

Genetically Engineered (T Cell Receptor) T Cells for Adoptive Therapy

Authors
  • Wang, Xinxin
  • Nishimura, Michael I.
Type
Book
Journal
Gene Therapy of Cancer
Publication Date
Jan 01, 2014
Pages
259–271
Identifiers
DOI: 10.1016/B978-0-12-394295-1.00018-4
ISBN: 978-0-12-394295-1
Source
Elsevier
Keywords
License
Unknown

Abstract

Studies have shown that adoptive transfer of ex vivo expanded tumor-infiltrating T lymphocytes (TIL) can mediate objective clinical responses in 50–70% of patients with advanced cancer. Due to practical limitations with TIL, we and others have genetically modified T cells to redirect their specificity to target cancer cells and viruses. Chimeric antigen receptors (CAR) were the first molecules used to redirect the specificity of T cells. CAR gene-modified T cells can target tumors in vitro and mediate tumor rejection in vivo in mice and humans. The second class of receptors used to redirect T cell specificity is the T cell receptor (TCR). Although not as thoroughly evaluated, TCR gene-modified T cells can also target tumors in vitro and mediate tumor rejection in vivo in mice and humans. This chapter discusses the development of CAR and TCR gene-modified T cells for use in treating cancer disease.

Report this publication

Statistics

Seen <100 times